---
title: "ACOG’s first menopause guideline since 2014 puts hormone therapy first"
description: "For women under 60, the reanalysed risks are low; the binding constraint is a shortage of the drugs"
author: "Luis Goa"
published: 2026-11-03T14:44:56.887Z
modified: 2026-11-03T17:24:07Z
url: https://rews.cc/a/acog-s-first-menopause-guideline-since-2014-puts-hormone-the-d48359
language: en
tags: ["menopause", "hrt", "fda", "estrogen", "health"]
publisher: "Rews (https://rews.cc)"
---

# ACOG’s first menopause guideline since 2014 puts hormone therapy first

*For women under 60, the reanalysed risks are low; the binding constraint is a shortage of the drugs*

By Luis Goa · November 3, 2026 · https://rews.cc/a/acog-s-first-menopause-guideline-since-2014-puts-hormone-the-d48359

## In brief

- ACOG’s Clinical Practice Guideline No. 13, its first menopause update since 2014, makes hormone therapy first-line for most patients
- Reanalysed data find hormone therapy risks highest after age 60 and “exceptionally low” for women under 60 or within 10 years of symptoms
- Nonhormonal options include SSRIs/SNRIs, new neurokinin receptor antagonists and, conditionally, cognitive behavioral therapy
- Federal officials are moving to drop FDA boxed warnings and approved generic Premarin and the first generic hormone patch
- Estrogen patches remain in shortage, with low generic margins giving manufacturers little incentive to increase supply

Half to nearly all women in menopause have symptoms: hot flashes, night sweats, mood swings, irregular periods, brain fog, skin changes. Between 16 and 66 percent report disrupted sleep, and more than a third of perimenopausal and postmenopausal women worldwide report symptoms of depression. Those are the numbers the American College of Obstetricians and Gynecologists attaches to its new menopause guideline, as [Sarah Rahal reported in the Boston Globe](https://bostonglobe.com/2026/11/03/metro/menopause-medical-perimenopause-changes-obgyn/). The prevalence was never in dispute. What changed is what doctors are now formally told to do about it.

## What the guideline says

The document is ACOG’s Clinical Practice Guideline No. 13, published in October in *Obstetrics & Gynecology*. It replaces Practice Bulletin No. 141 from 2014 — the first full update of ACOG’s menopause symptom guidance in more than a decade, according to [ACOG’s announcement](https://www.acog.org/news/2026/10/acog-expands-recommendations-for-management-of-menopause-symptoms). The core recommendation: for most patients without contraindications, hormone therapy should be the first-line treatment for hot flashes, sleep disturbance and related mood symptoms.

“It’s not really new, but it’s more formal,” said Dr. Deborah Susan Kwolek, a primary care physician who leads Mass General’s Women’s Health and Sex and Gender Medicine Program and is a Menopause Society certified practitioner. “We have ways to treat these symptoms.” Both ACOG and the American College of Physicians now call hormone therapy first-line, she noted, which gives doctors “permission to not be afraid of prescribing.”

Why the update now? “We’ve learned a lot in the last 10 years on risks and benefits, newer drugs have entered the market, and that made us look back at the data,” said ACOG’s Dr. Pier, quoted by the Globe. “This is a challenging review process, and making sure we have the highest quality recommendations takes time.”

![A gray-haired person seen from behind holds a square hand fan, with red and teal wavy lines suggesting heat and moving air.](https://rews.cc/img/6dacac381048710cd94d87515e3468a7a36b20dc.webp)

## The mechanism, and why the fear lingers

Hormone therapy replaces declining estrogen and, for some patients, adds progesterone or a related hormone. It comes as pills, patches, sprays, gels and vaginal rings. One of the oldest drugs, Premarin, is estrogen derived from the urine of pregnant horses; newer treatments typically use estradiol manufactured from plant-based materials. Menopause itself — the permanent stop of menstrual periods — typically arrives around age 50, but symptoms can start years earlier and persist years afterward; surgery, chemotherapy or radiation can trigger it early.

The prescribing fear traces to a specific event: a Women’s Health Initiative study in the early 2000s that linked hormone therapy to elevated risks of stroke and breast cancer. The newer analyses break the risk down by age, and on that breakdown the elevated risks were found to be concentrated in women older than 60, Pier said. For women under 60, or within 10 years of their first menopausal symptoms, the risk is “exceptionally low.” That timing window is the guideline’s central message. “This is where we can really guide our patients,” he said. Note what the evidence does and does not say: it is a risk gradient by age at initiation, measured in reanalysed trial data — not a declaration that hormone therapy is risk-free for everyone.

## Options for women who can’t take hormones

For patients who cannot or do not want to take hormonal drugs, SSRIs and SNRIs — two classes of antidepressants — are the typical recommendation. The guideline adds a newer FDA-approved class: neurokinin receptor antagonists, non-hormonal drugs that act on hot flashes in the brain. Pier cautioned that some non-hormonal options ease hot flashes and sleep problems but not vaginal dryness or irritation. For mood symptoms, cognitive behavioral therapy gets a conditional recommendation — a lower grade of evidence than the strong recommendations. Herbal supplements, Kwolek said, lack enough evidence to be recommended at all.

![A textured illustration shows a bed inside a dark blue brain, with a capsule protruding from the left and red wisps streaming outward.](https://rews.cc/img/f590870ba9f5bd65f7dd8c886a80ff3760504e3f.webp)

Two flags matter for patients with complicated histories. Tamoxifen, the breast cancer drug, can interact with some antidepressants. And breast cancer survivors or women with clotting disorders should raise their history with a doctor early, Pier said. If a doctor is dismissive, Kwolek suggests looking for clinicians carrying the Menopause Society’s “MSCP” designation — she says there are not enough of them, but the society’s website has a directory.

## Washington is moving in the same direction

The guideline lands as the federal government shifts its own posture. This month, officials announced steps to expand menopause treatment: efforts to strip the broad FDA boxed warnings from hormone therapies, approval of generic versions of Premarin and the first generic hormone therapy patch, Climara Pro, a newly approved non-hormonal drug for hot flashes, plus promotion of vaginal estrogen and expanded breast cancer screening initiatives. The boxed-warning removal, if completed, would erase the most visible residue of the early-2000s scare from the packaging itself.

## The shortage is the binding constraint

None of this helps much if the drug is not on the shelf. Estrogen patches remain in short supply, and Kwolek expects it to “get worse before it gets better.” The reason is structural: most estrogen products are generic, and she sees no significant financial incentive for manufacturers to ramp up production. That is the standard generics problem — multiple makers, thin margins, no one paid to hold spare capacity — now sitting on top of a guideline that tells doctors to prescribe more. Her practical advice: don’t go without. Many women can switch temporarily to pills, a spray or vaginal forms, and return to the patch when supply recovers.

![A red hand reaches toward a small square tag hanging from the rightmost hook on a dark blue wall rack.](https://rews.cc/img/28ee890601e855e9c39c3dab7390a565fef71fb9.webp)

## Testosterone, peptides, and the missing evidence

Testosterone has become a social media favourite for menopausal women, and patients are asking for it. Kwolek prescribes it sometimes but doesn’t push it. “The data is not convincing,” she said: it may improve sexual desire for some women, but the evidence behind other claims, such as building muscle, is weak. There is also no FDA-approved testosterone product for women, so every prescription is off-label, with extra paperwork. Pier added that more patients are arriving having already taken it: “We’re seeing patients who come in with misinformation or have been to facilities that provide off-label testosterone or other hormones, and we need to combat that with data.”

Peptides — marketed for sleep, weight loss, libido and longevity — are the newer trend, and none are FDA-approved for menopause. Kwolek draws the line plainly: “If I give you a prescription, I’m confident this will help you. If I recommend a supplement, I don’t know if it’ll help or hurt you.”

## The perimenopause gap

The guideline’s scope stops short of perimenopause — the years of irregular periods and shifting symptoms before periods end — even though that is the word patients now bring through the door. “Twenty years ago, people weren’t coming in saying, I’ve got perimenopause,” said Kwolek, who sees many such patients. Her read is that hormones are only part of the picture for exhausted, moody, badly sleeping women in their 40s and 50s: “You might have aches and pains from playing tennis too much, or your kids are keeping you up, or your parents are sick. The 40s and 50s sandwich generation is stretched thin.” There are also mundane, measurable causes to rule out: heavy periods can cause iron deficiency and fatigue. For some perimenopausal patients she prescribes contraception to manage symptoms.

The numbers to watch now are not in the guideline. They are on the supply side: whether removing boxed warnings expands demand for products whose generic makers have no margin-based reason to make more of them, and whether anyone — FDA or Congress — attaches an incentive to the patch shortage the way the guideline attaches confidence to the prescription.